

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
19 October 2006 (19.10.2006)

PCT

(10) International Publication Number
WO 2006/108591 A1

(51) International Patent Classification:

C07D 239/96 (2006.01) **C07D 307/16** (2006.01)
A61K 31/517 (2006.01) **C07D 309/12** (2006.01)
A61P 25/08 (2006.01) **C07D 231/12** (2006.01)
A61P 25/18 (2006.01) **C07D 249/06** (2006.01)
C07D 405/04 (2006.01) **C07D 207/32** (2006.01)
C07D 403/04 (2006.01) **C07D 307/54** (2006.01)
C07D 401/04 (2006.01) **C07D 237/08** (2006.01)
C07D 413/04 (2006.01)

41, CH-4054 Basel (CH). **KOLLER, Manuel** [CH/CH]; Fuhrenstrasse 16, CH-3098 Schliern (CH). **MATTES, Henri** [FR/FR]; 67, rue Damberg, F-68350 Brunstatt (FR). **NOZULAK, Joachim** [DE/DE]; In der Ziegelei 1, 79423 Heitersheim (DE). **ORAIN, David** [FR/FR]; 15, rue du Schweiberg, F-68220 Hesingue (FR). **RENAUD, Johanne** [CA/CH]; Blauensteinerstrasse 33, CH-4053 Basel (CH).

(21) International Application Number:

PCT/EP2006/003251

(22) International Filing Date: 10 April 2006 (10.04.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0507298.8 11 April 2005 (11.04.2005) GB

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; 35, Lichtstrasse, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALLGEIER, Hans** [DE/DE]; Lichsenweg 20, 79541 Lörrach (DE). **AUBERSON, Yves** [CH/CH]; Traubenweg 7, CH-4123 Allschwil (CH). **CARCACHE, David** [CH/CH]; Bruderholzstrasse 22, CH-4102 Binningen (CH). **FLOERSHEIM, Philipp** [CH/CH]; Engelgasse 47, CH-4052 Basel (CH). **GUIBOURDENCHE, Christel** [FR/CH]; Traugott Meyer Strasse 5, CH-4147 Aesch BL (CH). **FROESTL, Wolfgang** [AT/CH]; Holbeinstrasse 18/3, CH-4051 Basel (CH). **KALLEN, Jörg** [CH/CH]; Kaltbrunnenstrasse

(74) Agent: **GRIMM, Siegfried**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 1H-QUINAZOLINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS



(57) Abstract: The present invention relates to 1 H-Quinazoline-2,4-diones of formula (I) wherein R¹ and R² are as defined in the specification, their preparation, their use as AMPA-receptor ligands, in particular for the treatment of epilepsy or schizophrenia, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) and combinations comprising compounds of formula (I) are disclosed.